Keystone Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2013
Here are the related meetings in 2020:
PI3-Kinase and PTEN at the Interface of Cell Growth, Vesicular Trafficking and Disease (E1)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
PI 3-Kinase and Interplay with Other Signaling Pathways (X3)
Organizer(s) Christian Rommel, Kevan M. Shokat and José Baselga
February 24—March 1, 2013
Keystone Resort • Keystone, CO USA
Abstract Deadline: Oct 25, 2012
Late Abstract Deadline: Nov 28, 2012
Scholarship Deadline: Oct 25, 2012
Early Registration Deadline: Dec 19, 2012
Sponsored by Bayer USA Foundation, Gilead Sciences, Inc., Infinity Pharmaceuticals and Pfizer Inc.
Joint Meeting:
Tumor Metabolism (X4)
Summary of Meeting:
How metabolic pathways are regulated to meet the unique needs of tumor cells is not well understood, but mounting evidence suggests that metabolic regulation in cancer cells is intimately linked with the signal transduction pathways that control cell growth and proliferation. The PI3K-Akt-mTOR signaling pathway is one of the primary mechanisms for controlling tumor cell growth, survival, and motility in response to oncogenic signaling and extracellular cues. Genetic events resulting in inappropriate activation of this pathway are common in many cancers and, as a result, are a focus of both basic cancer research and drug discovery efforts in oncology. Although originally modeled as an independent and linear signaling cascade, today it is evident that the PI3K pathway also functions as a central hub for cross-talk in both vertical as well as reciprocal feedback regulation with other important signaling pathways. One of the most exciting advances in the field is the development of new inhibitors against this pathway. However, the rationale for inhibiting individual or multiple isoforms of PI3K/Akt/mTOR signaling remains a subject of intense debate. This meeting aims to bring together scientists and clinicians from academia and industry to discuss the opportunities and liabilities of targeting the PI3K- and related pathways in disease, drawing on human pathophysiology and genetics, preclinical models and clinical data with PI3K pathway inhibitors. A joint meeting addressing Tumor Metabolism will enhance opportunities for interdisciplinary interactions.
View Scholarships/Awards
How metabolic pathways are regulated to meet the unique needs of tumor cells is not well understood, but mounting evidence suggests that metabolic regulation in cancer cells is intimately linked with the signal transduction pathways that control cell growth and proliferation. The PI3K-Akt-mTOR signaling pathway is one of the primary mechanisms for controlling tumor cell growth, survival, and motility in response to oncogenic signaling and extracellular cues. Genetic events resulting in inappropriate activation of this pathway are common in many cancers and, as a result, are a focus of both basic cancer research and drug discovery efforts in oncology. Although originally modeled as an independent and linear signaling cascade, today it is evident that the PI3K pathway also functions as a central hub for cross-talk in both vertical as well as reciprocal feedback regulation with other important signaling pathways. One of the most exciting advances in the field is the development of new inhibitors against this pathway. However, the rationale for inhibiting individual or multiple isoforms of PI3K/Akt/mTOR signaling remains a subject of intense debate. This meeting aims to bring together scientists and clinicians from academia and industry to discuss the opportunities and liabilities of targeting the PI3K- and related pathways in disease, drawing on human pathophysiology and genetics, preclinical models and clinical data with PI3K pathway inhibitors. A joint meeting addressing Tumor Metabolism will enhance opportunities for interdisciplinary interactions.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
SUNDAY, FEBRUARY 24
MONDAY, FEBRUARY 25
TUESDAY, FEBRUARY 26
WEDNESDAY, FEBRUARY 27
THURSDAY, FEBRUARY 28
FRIDAY, MARCH 1
Conference Program Print | View meeting in 12 hr (am/pm) time
SUNDAY, FEBRUARY 24
19:15—21:30
Welcome and Keynote Session
*
José Baselga,
Memorial Sloan-Kettering Cancer Center, USA
08:00—09:00
Welcome and Keynote Address
*
Matthew G. Vander Heiden,
Massachusetts Institute of Technology, USA
Craig B. Thompson,
Memorial Sloan Kettering Cancer Center, USA
Metabolic Control of Tumor Cell Growth and Survival
Metabolic Control of Tumor Cell Growth and Survival
08:00—11:15
PI3K/Akt/mTOR Pathway in Cancer (Clinical - Part 1)
*
José Baselga,
Memorial Sloan-Kettering Cancer Center, USA
Breast Cancer
Breast Cancer
Brett S. Carver,
, USA
Targeting the PI3K and AR Pathways in Prostate Cancer: Defining Mechanisms of Response and Resistance
Targeting the PI3K and AR Pathways in Prostate Cancer: Defining Mechanisms of Response and Resistance
Vito J. Palombella,
Surface Oncology, USA
Development of the Potent PI3K-delta,gamma Inhibitor IPI-145
Development of the Potent PI3K-delta,gamma Inhibitor IPI-145
Khaled Ali,
Barts Cancer Institute, UK
Short Talk: Inactivation of p110delta PI 3-Kinase Releases Anti-Tumor Immune Responses
Short Talk: Inactivation of p110delta PI 3-Kinase Releases Anti-Tumor Immune Responses
Kyle A. Edgar,
Genentech, Inc., USA
Short Talk: Mechanisms of Acquired Resistance to the PI3K Inhibitor, GDC-0941 in Colorectal Cancer Cell Lines
Short Talk: Mechanisms of Acquired Resistance to the PI3K Inhibitor, GDC-0941 in Colorectal Cancer Cell Lines
09:00—11:00
Metabolic Regulation
*
Karen H. Vousden,
Francis Crick Institute, UK
Almut Schulze,
University of Würzburg/Theodor-Boveri Institute, Germany
The Role of Glucose and Lipid Metabolism in Growth and Survival of Cancer Cells
The Role of Glucose and Lipid Metabolism in Growth and Survival of Cancer Cells
Linda Z. Penn,
Princess Margaret Cancer Centre, Canada
The Mevalonate Pathway, Signaling and Tumor Vulnerability
The Mevalonate Pathway, Signaling and Tumor Vulnerability
Daniel S. Peeper,
Netherlands Cancer Institute, Netherlands
Short Talk: A Critical Role for the Mitochondrial Gatekeeper Pyruvate Dehydrogenase in Oncogene-Induced Senescence
Short Talk: A Critical Role for the Mitochondrial Gatekeeper Pyruvate Dehydrogenase in Oncogene-Induced Senescence
Jing Chen,
Winship Cancer Institute, Emory University, USA
Short Talk: Phosphoglycerate Mutase 1 Coordinates Glycolysis and Biosynthesis to Promote Tumor Growth
Short Talk: Phosphoglycerate Mutase 1 Coordinates Glycolysis and Biosynthesis to Promote Tumor Growth
14:30—16:30
Workshop 1: Metabolic Regulation and Adaptation
*
Matthew G. Vander Heiden,
Massachusetts Institute of Technology, USA
Brandon N. Nicolay,
Agios Pharmaceuticals, USA
Loss of RBF1 Changes Glutamine Catabolism
Loss of RBF1 Changes Glutamine Catabolism
Ming Yang,
Beatson Institute for Cancer Research, UK
Candidate Roles for Protein Succination in Altered Metabolism and Oncogenesis
Candidate Roles for Protein Succination in Altered Metabolism and Oncogenesis
Talya L. Dayton,
Massachusetts Institute of Technology, USA
Elucidating a Role for Pkm Isoform Expression Specificity in vivo
Elucidating a Role for Pkm Isoform Expression Specificity in vivo
Darin Salloum,
Memorial Sloan Kettering Cancer Center, USA
Human Cancer Cells Harboring Ras Mutations Display Elevated Requirement for Serum Lipids
Human Cancer Cells Harboring Ras Mutations Display Elevated Requirement for Serum Lipids
Wei Liu,
Frederick National Laboratory for Cancer Research, National Institutes of Health, USA
Proline Biosynthesis Augments MYC-Induced Aerobic Glycolysis and Cell Growth
Proline Biosynthesis Augments MYC-Induced Aerobic Glycolysis and Cell Growth
17:00—19:00
PI3K/Akt/mTOR Pathway (Clinical - Part 2)
Neal Rosen,
Memorial Sloan-Kettering Cancer Center, USA
Interplay Signaling
Interplay Signaling
Kui Lin,
Genentech, Inc., USA
Akt
Akt
Mark G. Manfredi,
Raze Therapeutics, USA
The Development of MLN0128, an Investigational mTOR Active Site Inhibitor
The Development of MLN0128, an Investigational mTOR Active Site Inhibitor
Kathryn Balmanno,
Babraham Institute, UK
Short Talk: Modelling Acquired Resistance to mTOR Kinase Inhibitors
Short Talk: Modelling Acquired Resistance to mTOR Kinase Inhibitors
17:00—19:00
Nutrient Sensing
*
Joan S. Brugge,
Harvard Medical School, USA
Eileen P. White,
Rutgers University, USA
Autophagy Maintains Mitochondrial Function and Tumorigenesis
Autophagy Maintains Mitochondrial Function and Tumorigenesis
Matthew G. Vander Heiden,
Massachusetts Institute of Technology, USA
Metabolic Pathways Important for Cell Growth
Metabolic Pathways Important for Cell Growth
David M. Sabatini,
Whitehead Institute for Biomedical Research
Large-Scale Approaches to Study Cancer Metabolism
Large-Scale Approaches to Study Cancer Metabolism
Issam Ben-Sahra,
Northwestern University, USA
Short Talk: Growth Signaling Stimulates Nucleotide Synthesis through mTOR
Short Talk: Growth Signaling Stimulates Nucleotide Synthesis through mTOR
08:00—11:15
PI3K/Akt/mTOR Pathway in Cancer (Clinical Translational)
*
Jeffrey A. Engelman,
Novartis Institutes for BioMedical Research, USA
Resistance Mechanisms
Resistance Mechanisms
Sebastian M. B. Nijman,
CeMM, Austrian Academy of Sciences, Austria
Gene-Drug Interaction Screens in Cancer
Gene-Drug Interaction Screens in Cancer
*
Lori Friedman,
ORIC Pharmaceuticals, USA
PI3K Inhibitor Combination Therapies
PI3K Inhibitor Combination Therapies
Jonathan M. Backer,
Albert Einstein College of Medicine, USA
GPCR–Mediated Activation of p110beta by Gbetagamma Is Required for Cellular Transformation and Invasiveness
GPCR–Mediated Activation of p110beta by Gbetagamma Is Required for Cellular Transformation and Invasiveness
Wayne A. Phillips,
Peter MacCallum Cancer Centre, Australia
Short Talk: Ubiquitous Expression of a Heterozygous Pik3ca Mutation Results in Increased Body Size, Hypoglycemia and Sudden Death
Short Talk: Ubiquitous Expression of a Heterozygous Pik3ca Mutation Results in Increased Body Size, Hypoglycemia and Sudden Death
Mamatha Bhat,
University Health Network, Canada
Short Talk: Metformin Induces Apoptosis of Hepatocellular Carcinoma Downstream of mTORC1 through eIF4E
Short Talk: Metformin Induces Apoptosis of Hepatocellular Carcinoma Downstream of mTORC1 through eIF4E
08:00—11:15
Metabolic Adaptation
*
David M. Sabatini,
Whitehead Institute for Biomedical Research
Brian J. Altman,
University of Rochester, USA
Regulation of Cell Growth and Metabolism by Myc
Regulation of Cell Growth and Metabolism by Myc
Zachary Schug,
Wistar Institute, USA
Targeting Lipid Metabolism in Breast Cancer
Targeting Lipid Metabolism in Breast Cancer
Reuben J. Shaw,
The Salk Institute for Biological Studies, USA
The LKB1 Tumor Suppressor Pathway: Decoding Metabolic Links and Therapeutic Targeting
The LKB1 Tumor Suppressor Pathway: Decoding Metabolic Links and Therapeutic Targeting
Costas A. Lyssiotis,
University of Michigan, USA
Short Talk: Glutamine Metabolism Supports Pancreatic Tumor Growth and Redox Homeostasis
Short Talk: Glutamine Metabolism Supports Pancreatic Tumor Growth and Redox Homeostasis
Zhimin Lu,
University of Texas MD Anderson Cancer Center, USA
Short Talk: The Warburg Effect and Beyond
Short Talk: The Warburg Effect and Beyond
17:00—19:00
PI3K/mTOR Pathway - Signaling Networks (Preclinical)
*
Kevan M. Shokat,
University of California, San Francisco, USA
Chemical Genetic Investigations of Protein and Lipid Kinase Signaling
Chemical Genetic Investigations of Protein and Lipid Kinase Signaling
John Blenis,
Weill Cornell Medical College, USA
Convergence and Integration of mTOR and Ras-ERK Signaling in Cancer
Convergence and Integration of mTOR and Ras-ERK Signaling in Cancer
David M. Sabatini,
Whitehead Institute for Biomedical Research, USA
Regulation of Growth by the mTOR Pathway
Regulation of Growth by the mTOR Pathway
Tamara Chessa,
Babraham Institute, UK
Short Talk: Dissecting the ClassIA PI3K Signalosome
Short Talk: Dissecting the ClassIA PI3K Signalosome
17:00—19:00
Understanding the Metabolic Network
*
Ralph J. DeBerardinis,
University of Texas Southwestern Medical Center, USA
Tomer Shlomi,
Technion, Israel
An Integrated Computational-Experimental Approach for Finding Metabolic Synthetic Lethality in Cancer
An Integrated Computational-Experimental Approach for Finding Metabolic Synthetic Lethality in Cancer
Linda C. Hsieh-Wilson,
California Institute of Technology, USA
Linking O-GlcNAc Signaling to Cancer Metabolism and Tumor Growth
Linking O-GlcNAc Signaling to Cancer Metabolism and Tumor Growth
Stefan Kempa,
Max Delbrück Center for Molecular Medicine, Germany
Short Talk: Quantifying Metabolic Routes in Cancer Cells Using Pulsed Stable Isotope Resolved Metabolomics (pSIRM)
Short Talk: Quantifying Metabolic Routes in Cancer Cells Using Pulsed Stable Isotope Resolved Metabolomics (pSIRM)
08:00—11:15
PI3K-Related Pathways (Preclinical)
*
Lewis C. Cantley,
Weill Cornell Medicine, USA
PI 3-Kinase, AMPK and Disease
PI 3-Kinase, AMPK and Disease
Judith A. Varner,
University of California, San Diego, USA
PI3K gamma Control of Innate Immunity in Cancer
PI3K gamma Control of Innate Immunity in Cancer
Karen M. Cichowski,
Brigham and Women's Hospital, Harvard Medical School, USA
Developing Combination Therapies with PI3K/mTOR Pathway Inhibitors
Developing Combination Therapies with PI3K/mTOR Pathway Inhibitors
Hong Wu,
UCLA/IMED c/o Cyndi Haddad, USA
Cross-Talk between the PI3K and MAPK Pathways Determines Prostate Cancer Metastasis
Cross-Talk between the PI3K and MAPK Pathways Determines Prostate Cancer Metastasis
Kira Gritsman,
Albert Einstein College of Medicine, USA
Short Talk: RAS-Mutated Myeloid Leukemias Are Dependent on the PI3 Kinase Isoform p110alpha
Short Talk: RAS-Mutated Myeloid Leukemias Are Dependent on the PI3 Kinase Isoform p110alpha
Maurizio Scaltriti,
Memorial Sloan-Kettering Cancer Center, USA
Short Talk: p90RSK Mediates Resistance to PI3K-Pathway Inhibitors in Breast Cancer
Short Talk: p90RSK Mediates Resistance to PI3K-Pathway Inhibitors in Breast Cancer
08:00—11:00
Influence of the Microenvironment on Metabolism
*
Sally A. Kornbluth,
Duke University Medical Center, USA
Jacques Pouysségur,
University of Nice, France
Hypoxia Signaling, pHi Regulation and Tumor Metabolism: Novel Therapeutic Approaches
Hypoxia Signaling, pHi Regulation and Tumor Metabolism: Novel Therapeutic Approaches
M. Celeste Simon,
University of Pennsylvania, USA
Tumor Cell Adaptation to the Microenvironment
Tumor Cell Adaptation to the Microenvironment
Amato J. Giaccia,
Stanford University, USA
Oxygen Sensing and Metabolic Control
Oxygen Sensing and Metabolic Control
Brendan D. Manning,
Harvard School of Public Health, USA
Tumor Cell Intrinsic Biosynthesis Driven by mTOR Signaling
Tumor Cell Intrinsic Biosynthesis Driven by mTOR Signaling
Russell G. Jones,
Van Andel Research Institute, USA
Short Talk: AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth in vivo
Short Talk: AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth in vivo
17:00—19:00
PI3K Pathway: Cross-Talk, Feedback, Scaffold (Preclinical)
Julian H. Downward,
Cancer Research UK, UK
Links between RAS Family GTPases and PI3K Signaling
Links between RAS Family GTPases and PI3K Signaling
Pier Paolo Pandolfi,
Beth Israel Deaconess Medical Center, Harvard Medical School, USA
Role of Mutant PTEN in Tumorigenesis
Role of Mutant PTEN in Tumorigenesis
John P. O'Bryan,
Medical University of South Carolina, USA
Short Talk: PI3KC2beta: Role in Tumorigenesis and Regulation by Nucleotide-Ras (nf-Ras)
Short Talk: PI3KC2beta: Role in Tumorigenesis and Regulation by Nucleotide-Ras (nf-Ras)
17:00—19:15
Insights from in vivo Experiments
*
M. Celeste Simon,
University of Pennsylvania, USA
Tak W. Mak,
Campbell Family Institute for Breast Cancer, Canada
Tumor Metabolism: Insight from Mouse Models
Tumor Metabolism: Insight from Mouse Models
Yanping Zhang,
University of North Carolina at Chapel Hill, USA
The RP-Mdm2-p53 Pathway Links Nutrient Restriction to Lipid Homeostasis
The RP-Mdm2-p53 Pathway Links Nutrient Restriction to Lipid Homeostasis
Ralph J. DeBerardinis,
University of Texas Southwestern Medical Center, USA
Measuring Metabolism and Metabolites in vivo
Measuring Metabolism and Metabolites in vivo
Norman Koglin,
Piramal Imaging GmbH, Germany
PET Imaging of Glutamate/Cystine Transporter Activity in Cancer Patients
PET Imaging of Glutamate/Cystine Transporter Activity in Cancer Patients
08:00—11:15
PI3K-Related Pathways (Preclinical)
*
Bart Vanhaesebroeck,
University College London, Cancer Institute, UK
PI 3-Kinase Isoforms in Cancer and Metabolism
PI 3-Kinase Isoforms in Cancer and Metabolism
Davide Ruggero,
University of California, San Francisco, USA
Reprogramming Translational Control of mRNA Networks in Cancer and its Therapeutic Implications
Reprogramming Translational Control of mRNA Networks in Cancer and its Therapeutic Implications
Jonathan R. Hart,
The Scripps Research Institute, USA
Pulsed SILAC: Enabling the Direct Observation of Changes in Protein Synthesis Caused by mTOR Inhibition
Pulsed SILAC: Enabling the Direct Observation of Changes in Protein Synthesis Caused by mTOR Inhibition
William A. Weiss,
University of California, San Francisco, USA
Kinases in Autophagy as Therapeutic Targets in Brain Cancer
Kinases in Autophagy as Therapeutic Targets in Brain Cancer
Vikki Flemington,
AstraZeneca, UK
Short Talk: Phosphatidylinositol-4-Kinase – Potent and Selective Inhibitors of Type III PI 4-Kinases
Short Talk: Phosphatidylinositol-4-Kinase – Potent and Selective Inhibitors of Type III PI 4-Kinases
Emilio Hirsch,
Fondazione per la Ricerca Biomedica – ONLUS, Italy
Short Talk: PI3K Class II alpha Controls Primary Cilium Function and Cell Proliferation in Development and Cancer
Short Talk: PI3K Class II alpha Controls Primary Cilium Function and Cell Proliferation in Development and Cancer
08:00—11:00
Targeting Metabolism
*
Jacques Pouysségur,
University of Nice, France
Bing Lim,
Genome Institute of Singapore, Singapore
Targeting Glycine Metabolism for Cancer Therapy
Targeting Glycine Metabolism for Cancer Therapy
Susan E. Critchlow,
AstraZeneca, UK
Targeting Lactate Metabolism in Cancer
Targeting Lactate Metabolism in Cancer
Sally A. Kornbluth,
Duke University Medical Center, USA
Metabolic Control of Caspase 2-Mediated Cell Death
Metabolic Control of Caspase 2-Mediated Cell Death
Joan S. Brugge,
Harvard Medical School, USA
Use of 3D Culture Models to Understand the Impact of Targeted Therapy on Metabolism
Use of 3D Culture Models to Understand the Impact of Targeted Therapy on Metabolism
Georgia Hatzivassiliou,
Genentech, Inc., USA
Short Talk: Dissecting the Role of Glutaminase in Cancer
Short Talk: Dissecting the Role of Glutaminase in Cancer
Genshi Zhao,
Eli Lilly and Company, USA
Short Talk: Pharmacological Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, in Human Cancer Cells: Metabolic Basis and Potential Clinical Implications
Short Talk: Pharmacological Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, in Human Cancer Cells: Metabolic Basis and Potential Clinical Implications
15:00—16:30
Workshop 2: Novel Therapeutic Approaches
*
Katharine Yen,
Auron Therapeutics, USA
Steve Colebrook,
Cancer Research UK, UK
A First-in-Man Phase I Trial of AZD3965, a Monocarboxylate Transporter 1 Inhibitor (MCT1), in Patients with Advanced Cancer
A First-in-Man Phase I Trial of AZD3965, a Monocarboxylate Transporter 1 Inhibitor (MCT1), in Patients with Advanced Cancer
Krushna C. Patra,
Massachusetts General Hospital, Harvard Medical School, USA
Hexokinase 2 Is Required for Oncogenesis and its Systemic Deletion Is Therapeutic in Mouse Models of Cancer
Hexokinase 2 Is Required for Oncogenesis and its Systemic Deletion Is Therapeutic in Mouse Models of Cancer
Alexandra R. Grassian,
Novartis Institutes for BioMedical Research, USA
Mutant Isocitrate Dehydrogenase Promotes a Reversible Epithelial-Mesenchymal Transition and Alters Metabolic Flux
Mutant Isocitrate Dehydrogenase Promotes a Reversible Epithelial-Mesenchymal Transition and Alters Metabolic Flux
Kelly E. Sullivan,
Cornell University, USA
Elucidating the Regulation of Mitochondrial Glutaminase in Cancer Progression
Elucidating the Regulation of Mitochondrial Glutaminase in Cancer Progression
David R. Plas,
University of Cincinnati, USA
Transition to Fatty Acid Oxidation Mediates Survival of BCR-ABL-Transformed Cells after Inhibition of mTORC1-S6K1
Transition to Fatty Acid Oxidation Mediates Survival of BCR-ABL-Transformed Cells after Inhibition of mTORC1-S6K1
17:00—19:00
PI3K-Related Pathways (Preclinical)
*
David A. Fruman,
University of California, Irvine, USA
Immune Effects of Anti-Cancer Drugs Targeting PI3K/mTOR
Immune Effects of Anti-Cancer Drugs Targeting PI3K/mTOR
Brendan D. Manning,
Harvard School of Public Health, USA
Linking Oncogenic Signaling to Anabolic Metabolism through mTOR
Linking Oncogenic Signaling to Anabolic Metabolism through mTOR
Ramon Parsons,
Icahn School of Medicine at Mount Sinai, USA
PTEN Signaling
PTEN Signaling
Ralph M. Fritsch,
Cancer Research UK London Research Institute, UK
Short Talk: RAS and RHO Family GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms
Short Talk: RAS and RHO Family GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms
17:00—19:00
Influence of Metabolism on Epigenetic Regulation
*
Matthew G. Vander Heiden,
Massachusetts Institute of Technology, USA
Lewis C. Cantley,
Weill Cornell Medicine, USA
Metabolic Control of Histone Methylation
Metabolic Control of Histone Methylation
Katharine Yen,
Auron Therapeutics, USA
Mutation Selective IDH Inhibitors Mediate Histone and DNA Methylation Changes
Mutation Selective IDH Inhibitors Mediate Histone and DNA Methylation Changes
Raul Mostoslavsky,
Harvard Medical School, USA
Short Talk: The Histone Deacetylase SIRT6 Suppresses Cancer Metabolism
Short Talk: The Histone Deacetylase SIRT6 Suppresses Cancer Metabolism
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors for generously supporting this meeting:
|
|
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
|
Echelon Biosciences, Inc. |
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
